Figures
Abstract
Background
Ventilation monitoring during sleep is performed by sleep test instrumentation that is uncomfortable for the patients due to the presence of the flowmeter. The objective of this study was to evaluate if an innovative type 3 wearable system, the X10X and X10Y, is able to correctly detect events of apnea and hypopnea and to classify the severity of sleep apnea without the use of a flowmeter.
Methods
40 patients with sleep disordered breathing were analyzed by continuous and simultaneous recording of X10X and X10Y and another certified type 3 system, SOMNOtouch, used for comparison. Evaluation was performed in terms of quality of respiratory signals (scores from 1, lowest, to 5, highest), duration and classification of apneas, as well as identification and duration of hypopneas.
Results
580 periods were evaluated. Mean quality assigned score was 3.37±1.42 and 3.25±1.35 for X10X and X10Y and SOMNOtouch, respectively. The agreement between the two systems was evaluated with grades 4 and 5 in 383 out of 580 cases. A high correlation (r2 = 0.921; p<0.001) was found between the AHI indexes obtained from the two systems. X10X and X10Y devices were able to correctly classify 72.3% of the obstructive apneas, 81% of the central apneas, 61.3% of the hypopneas, and 64.6% of the mixed apneas when compared to SOMNOtouch device.
Citation: Contini M, Sarmento A, Gugliandolo P, Leonardi A, Longinotti-Buitoni G, Minella C, et al. (2021) Validation of a new wearable device for type 3 sleep test without flowmeter. PLoS ONE 16(4): e0249470. https://doi.org/10.1371/journal.pone.0249470
Editor: James Andrew Rowley, Harper University Hospital, UNITED STATES
Received: September 3, 2020; Accepted: March 18, 2021; Published: April 16, 2021
Copyright: © 2021 Contini et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting information files.
Funding: L.I.F.E. Italia S.r.l. and L.I.F.E. Corporation S.A. provided financial support in the form of authors’ salaries for AL, GLB, and CM, and research materials. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders did not play a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Dr. Longinotti-Buitoni and Dr. Aliverti are inventors in patents related to the submitted work (Patents number US20200323285, US20200068708, US20180376586, US20180184735, US9282893). Dr. Aliverti received consultancy fees from L.I.F.E. Corporation S.A. outside the submitted work. Dr. Agostoni has non-financial support from Menarini, grants from Daiichi Sankyo, nonfinancial support from Novartis, non-financial support from Boeringer, grants and nonfinancial support from Actelion, and grants from Bayer, outside the work presented in this article. This does not alter the adherence to PLOS ONE policies on sharing data and materials.
Introduction
There is growing evidence regarding the need for ventilation monitoring during sleep [1–5]. Indeed the presence of sleep apnea is associated with a poor prognosis as well as therapy failure in several diseases such as neurological disorders, heart failure, cardiac arrhythmias, and hypertension [6–11]. Most importantly, sudden death has also been associated with nocturnal hypoxia [12,13]. While monitoring ventilation during sleep, it is important to assess the total number of apneas and hypopneas including their duration, and to distinguish the central, obstructive and mixed apneas according to their varying causes and treatments [14,15]. Finally, ventilation monitoring during sleep is currently performed with various types of sleep tests which, above type 4 (monitoring of oxygen-hemoglobin saturation), implies a relatively uncomfortable experience for the patients considering the complex instrumentation used to measure ventilation [16,17].
Abnormalities of daytime ventilation, either at rest or during exercise, have also been reported albeit studied to a much lesser extent. Indeed, the ability to monitor ventilation during the daytime is limited and specifically, it is difficult to conceive prolonged ventilation measurements through any sort of flow meter during daytime activity [18–20]. Accordingly, there is a need for comfortable and unobtrusive ventilation recording devices capable of quantifying and characterizing ventilation abnormalities, for both day and night [21,22].
In a recent study from our group, we evaluated an innovative wearable device for ECG and respiratory Holter monitoring, which allows noninvasive, continuous, simultaneous, prolonged and accurate monitoring of cardiorespiratory signals [23]. However, no direct comparison with commercially available ventilation recording systems has been done yet. The previous version of this sensorized garment has been upgraded to improve respiratory recording by implementing circumferential sensors instead of linear and local strain gauges. Both ECG and respiratory sensors are woven into the fabric of the self-wearable, and easily washable, fitted garment. The current study was aimed to simultaneously record and compare one standard type 3 system, allowing respiratory movement and airflow measurements through a nasal pressure cannula, with a proposed innovative wearable type 3 system based on respiratory movement measurements only, deriving ventilation from three respiratory sensors embedded in its fabric. More specifically, we evaluated the detection, duration, and classification of apneas, as well as the identification and duration of hypopneas.
Methods
This is a cross-sectional study conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the ethics committee of the Centro Cardiologico Monzino, IRCCS, Milan, Italy (CCM589). Prior to participating in the study, all patients gave written, signed, and informed consent.
Study inclusion criteria were: age 18–90 years, presence of cardiovascular disease requiring hospitalization and previous diagnosis of moderate to severe sleep apnea/hypopnea assessed by standard polysomnography. Patients using continuous oxygen therapy or with neuromuscular diseases were excluded. All subjects who had access to the Centro Cardiologico IRCCS severe heart failure outpatient unit (between May 2018 and January 2019) and meet the study inclusion/exclusion criteria were asked to participate to the present study.
Measurements
X10X and X10Y medical devices (L.I.F.E. Italia s.r.l., Milano, Italy) is composed of 10 ink-based dry electrodes to monitor ECG, three respiratory strain sensors, one inertial measurement unit (IMU) and a pulse oximeter (Nonin Medical, Minnesota, USA) (Fig 1). For this study, only the respiratory sensors and the oximeter data were analyzed. The respiratory sensors are made of a conductive rubber completely embedded in the garment and positioned circumferentially around the body at thoracic level (level of the manubrium), xiphoid process level, and abdominal level (between the lower costal margin and the umbilical level) (Fig 1). The sensors provide electrical resistance variations measured at a sampling rate of 50 Hz. The devices tested in this study were X10X (version for female subjects) and X10Y (version for male subjects). Both versions have the same number of sensors, hardware and firmware, however, they are characterized by sartorial differences driven by anatomical and ergonomic differences. The female device, in particular, has a specific design enhancing breast support obtained by a light sartorial structure incorporating the cups designed to optimise the contact of both ECG and thoracic respiration circumferential sensors to the skin, thus securing data accuracy even during daily activities/movements. Data of X10X and X10Y devices were analyzed exactly in the same way. Thereafter we refer to X10X-Y device.
The garment embeds ten ink-based dry electrodes (red points) to provide 12 lead ECG and three respiratory strain sensors positioned circumferentially around the body at thoracic level (level of the manubrium, TRX), xiphoid process level (XIP), and abdominal level (between the lower costal margin and the umbilical level, AB).
The SOMNOtouch™ RESP device (Somno SOMNOmedics GmbH, Randersacker, Germany) is composed of a nasal cannula, a pulse oximeter, two respiratory sensors that are positioned at the level of the manubrium and abdomen, and three thoracic electrodes for ECG recording.
Study protocol
The protocol consisted of a continuous and simultaneous recording of traces from the two devices. All patients wore the SOMNOtouchTM RESP bands and the X10X-Y device in the laboratory at Monzino Hospital where they received practical instructions and where the functioning of the devices was tested by expert medical personnel. After the patients wore the X10X-Y device, signal quality was checked. Thereafter, the SOMNOtouchTM RESP bands were positioned onto the X10X-Y device and all signals were checked again. Only when both devices were judged to provide good quality signals, patients were sent to their home. All recruited patients wore the two devices (X10X-Y and SOMNOtouch™ RESP) in the early afternoon, but data acquisition, of both devices was therefore simultaneous and began according to the patients’ sleep habits (usually around 10 pm). The SOMNOtouch™ RESP nasal cannula and the finger probes of both instruments were checked, and patients were instructed to wear these devices by themselves just before going to sleep.
Acquisitions started automatically at the set time and lasted all night long: SOMNOtouch™ RESP acquisitions ended at the pre-configured time, previously agreed with the patient, while X10X-Yacquisitions were stopped manually before the removal of the garment in the morning.
X10X and X10Y and pulse-oximetry raw data were downloaded from the logger and the watch via USB cables, respectively, stored into a repository on a PC and successively analyzed. Both SOMNOtouch™ RESP and X10X-Y data were processed following the standard procedure provided by dedicated software in order to detect obstructive, central and mixed apneas and hypopneas events, and two expert operators successively validated the results produced by automatic analysis.
Data analysis
Analysis was divided into two parts. The first analysis was a qualitative one. Respiratory signals from SOMNOtouch™ RESP and X10X-Y devices were synchronized on the basis of the two on-board clocks. Data regarding respiratory sum signal of both devices (sum of three signals in the X10X-Y devices, and of two signals in the SOMNOtouch™ RESP device) were analyzed qualitatively by two experts, and in the case of different scores, they were averaged. More specifically, every 30 minutes, an interval of 8 minutes was analyzed by giving grades that ranged from 1 to 5, i.e. 1 = poor signal and difficult interpretation; 2 = insufficient signal and questionable interpretation; 3 = sufficient signal and reliable interpretation; 4 = good signal and reliable interpretation; 5 = excellent signal and reliable interpretation. An analogous 1 to 5 grading was carried out in order to describe the level of agreement between the quality of SOMNOtouch™ RESP and X10X-Y respiratory sum signals. A set of figures reporting examples of grade 1 to 5 is reported in the supplemental file material as S1–S5 Figs.
The second analysis, also performed by two expert operators, was a quantitative one. The data derived from SOMNOtouch™ RESP were automatically processed by SOMNOMedics software for detection of sleep respiratory disorders. Respiratory event scoring was then manually confirmed according to the most recent guidelines [24], considering the signals of the thoracoabdominal bands, the flowmeter and the pulse-oximeter. The data derived from X10X-Y devices, after filtering them with a pass band filter 0.045–1 Hz, were processed in a similar way but only using the three thoracoabdominal bands together with their sum and oxygen saturation signal. Similarly, the first step was an automatic apneas and hypopneas (‘events’) detection by X10X-Y software, based on the following criteria definitions:
- event: minimum duration of 10 seconds and ≥3% oxygen desaturation [24];
- hypopnea: signal excursion drop by ≥30% with respect to the previous minute;
- central apnea: signal excursion drop by ≥80% with respect the previous minute;
- obstructive apnea: signal excursion drop by ≥50% with respect to the previous minute, in presence of thoraco-abdominal asynchrony (phase angle > 36 degrees);
- mixed apnea: signal excursion drop by ≥50% with respect to the previous minute, with an initial phase without efforts followed by a second phase with efforts (presence of thoraco-abdominal asynchrony).
After automatic analysis performed by the software, respiratory event scoring was successively manually confirmed according to the most recent guidelines [24]. In detail, the criteria used for hypopneas were the ones classified in [24] as 1A (“Scoring of Hypopneas” section), namely: a) the peak signal excursion drop by ≥30% of pre-event baseline using an alternative hypopnea sensor; b) the duration of the ≥30% drop in signal excursion is ≥10 seconds; c) there is a ≥3% oxygen desaturation from pre-event baseline or the event is associated with an arousal.
Examples of signals recorded by the two devices during events of hypopnea, central, obstructive and mixed apneas are shown in Figs 2–5.
From top to bottom: flow (measured by SOMNOtouch device); sum signal (thoracic + abdominal) obtained from SOMNOtouch device; thoracic (blue) and abdominal (orange) signals from SOMNOtouch device; oxygen saturation from pulse oximeter; sum signal (thoracic +xiphoid + abdominal) obtained from X10X-Y device; thoracic (blue), xiphoid (orange) and abdominal (green) signals from X10X-Y device.
From top to bottom: flow (measured by SOMNOtouch device); sum signal (thoracic + abdominal) obtained from SOMNOtouch device; thoracic (blue) and abdominal (orange) signals from SOMNOtouch device; oxygen saturation from pulse oximeter; sum signal (thoracic +xiphoid + abdominal) obtained from X10X-Y device; thoracic (blue), xiphoid (orange) and abdominal (green) signals from X10X-Y device.
From top to bottom: flow (measured by SOMNOtouch device); sum signal (thoracic + abdominal) obtained from SOMNOtouch device; thoracic (blue) and abdominal (orange) signals from SOMNOtouch device; oxygen saturation from pulse oximeter; sum signal (thoracic +xiphoid + abdominal) obtained from X10X-Y device; thoracic (blue), xiphoid (orange) and abdominal (green) signals from X10X-Y device.
From top to bottom: flow (measured by SOMNOtouch device); sum signal (thoracic + abdominal) obtained from SOMNOtouch device; thoracic (blue) and abdominal (orange) signals from SOMNOtouch device; oxygen saturation from pulse oximeter; sum signal (thoracic +xiphoid + abdominal) obtained from X10X-Y device; thoracic (blue), xiphoid (orange) and abdominal (green) signals from X10X-Y device.
Apnea-hypopnea index (AHI) was graded as mild (≥5 and <15 events/hour), moderate (≥15 and <30) and severe (≥30) [24]. After the operator’s correction, the set of events detected by SOMNOtouch™ RESP and X10X-Y devices were compared and classified as true positive (TP, when both systems detected the same type of event at the same time), false positive (FP, when an event of a specific type detected by the X10X-Y devices, was not detected by the SOMNOtouch™ RESP device), and false negative (FN, when an event of a specific type detected by the SOMNOtouch™ RESP system, was not detected by the X10X-Y devices).
Statistical analysis
Data normality was verified using the Shapiro-Wilk test. Metrics of sensitivity (SE) and positive predictivity (+P) were used to summarize the results of comparison as follows:
A 5x5 confusion matrix was used to cross-validate the detected events during sleep (i.e. hypopneas, obstructive, central, and mixed apneas) between devices. Agreement regarding AHI between SOMNOtouch™ RESP and X10X-Y were evaluated using Bland-Altman plot, and the results were presented as bias with limits of agreement (±1.96 STD). In order to observe if the limits were acceptable, the 95% confidence interval was calculated for both bias and limits of agreement according to Giavarina [25]. Correlations were studied using Pearson correlation coefficient and both coefficients of correlation (r) and determination (r2) were calculated.
Data analysis was performed using Python scipy library (submodule stats) version 1.2.1. A p-value of <0.05 (2-sided) was considered statistically significant.
Results
Forty-six patients were recruited (42 males, 4 females). Median age was 69 years (STD 11 years, range 39–85 years). Of these, 6 patients were excluded for different reasons: the lack of SpO2 recording (3 patients), the refusal to perform the exams (2 patients) and the failure of the acquisition (1 patient) (Fig 6). Demographic and clinical characteristics of the 40 patients who concluded the study are reported in Table 1. Average AHI at the pretest evaluation was 25.77±9.68 which included obstructive, central and mixed apneas (Table 1).
Mean quality assigned score was 3.37±1.42 and 3.25±1.35 for X10X-Y and SOMNOtouch™ RESP, respectively. Higher values of quality assessment (grades 4 and 5, S4 and S5 Figs, online supplement) were more frequently assigned to X10X-Y than to SOMNOtouch™ RESP recordings, while the opposite occurred for lower grades (1 and 2) (S1 and S2 Figs, online supplement). A good agreement, (grades 4 and 5) was observed in most cases (383/580).
All included patients AHI were graded as mild, moderate and severe with X10X-Y in 10, 9, and 12 patients, respectively, while SOMNOtouch™ RESP graded the same AHI in 10, 10, and 11 patients (Fig 7). Apnea/hypopnea was not observed in seven cases by both devices. Five out of 38 patients were classified differently by the two devices. Specifically, 3 patients classified as “mild” by X10X-Y, were classified by SOMNOtouch™ RESP as “normal” in two cases and “moderate” in one case; two patients classified as “normal” and “moderate” by X10X-Y, were classified as “mild” by the SOMNOtouch™ RESP, and two patients classified as “severe” by X10X-Y, were classified as “moderate” by SOMNOtouch™ RESP. Nevertheless a high correlation (r = 0.960; r2 = 0.921; p<0.001) and a good agreement (mean bias -0.77±4.39) were found between devices.
Left panel: Correlation between apnea hypopnea index (AHI) observed with X10X and X10Y and SOMNOtouch™ RESP devices. Squares represent areas of agreement in the AHI severity classification. Right Panel: Bland-Altman plot of AHI detected by X10X and X10Y and SOMNOtouch™ RESP devices. Confidence intervals of bias and limits of agreement are shown.
Average recording duration was 7.4±1.1 h. When considering all events detected by X10X-Y device, the X10X-Ydevice was able to correctly classify 72% of the obstructive apneas, 81% of the central apneas, 61% of the hypopneas, and 64.6% of the mixed apneas when compared to the SOMNOtouch™ RESP device (Table 2). When considering all events detected by SOMNOtouch, the X10X-Y device was able to correctly classify 56% of the obstructive apneas, 69% of the central apneas, 38% of the hypopneas, and 56% of the mixed apneas when compared to the SOMNOtouch™ RESP device (Table 2).
The SE and +P of X10X-Y in identifying a total number of events was 78% and 76%, respectively (Table 3).
Discussion
Our study compared a new wearable device for the simultaneous recording of multiple cardiorespiratory signals (X10X-Y devices) to an approved type 3 recording sleep device, a well-established, and widely used nocturnal cardiorespiratory monitoring system in the clinical field (SOMNOtouch™ RESP). We showed that X10X-Y are able to provide during sleep reliable respiratory signals, reliable classification of patients apnea severity and accurate classification of apnea/hypopnea events.
Some operating differences between the two devices need to be acknowledged:
- X10X-Y devices are based on an easily wearable garment with sensors integrated into the fabric so that their position is reliable and consistent throughout the recording period. Differently, the respiratory bands in the SOMNOtouch™ RESP system, as well as other commercial sleep devices, face the possibility of band dislodgment;
- In the SOMNOtouch™ RESP system, respiratory flow is directly recorded by a nasal cannula measuring changes in nasal air pressure during ventilation, which are used to detect and classify sleep events. In X10X-Y devices, conversely, respiratory flow is derived from an integrated analysis of respiratory movements detected at three different levels of the thoraco-abdominal wall;
- In SOMNOtouch™ RESP system, classification of apneas is made by simultaneous analysis of the behavior of respiratory flow and respiratory thoracic and abdominal respiratory movements. This is because a central apnea is detected when both airflow and respiratory movements are absent, and obstructive when airflow is absent in the presence of thoracic and/or abdominal respiratory movement. Conversely, in the X10X-Y devices, both central and obstructive apneas are characterized by a flattening of the sum signal of respiratory movement traces, but an obstructive event is recognized if abdominal and thoracic movements are out of phase (S3 Fig, online supplement). This is the reason why in our X10X-Y device, we have differentiated the threshold used to detect central apneas and obstructive apneas in order to be as sensitive as possible, i.e. to detect the highest possible number of events when characterizing a patients in terms of AHI.
The qualitative analysis showed a slightly higher quality of the X10X-Y respiratory sum signal in comparison to the one recorded by the SOMNOtouch™ RESP system. The sensors embedded in X10X-Y fitted garment are positioned more firmly, and this likely account for the difference.
As for quantitative analysis, despite the reported technical differences in the system operating features, a good correlation has been found in AHI determination between the two devices. Moreover, the severity grading for respiratory disorders showed a very high agreement between the SOMNOtouch™ RESP and X10X-Y devices. Indeed, in only 5 patients out of 40 (12.5%) severity disease estimation differed between the two devices and in all cases, the difference was of only one class of severity. Notably in all but one patient with severe apnea/hypopnea as well as in all patients with no sleep abnormalities X10X-Y properly detected the sleep severity of the sleep disorder.
It is noteworthy that the correct detection of sleep apneas/hypopneas severity with X10X-Y devices, as validated by agreement with SOMNOtouch™ RESP event detection, was obtained in the absence of a direct respiratory airflow recorded by a nasal cannula [16,18,22]. Avoiding the application of a nasal cannula is highly favorable from several points of view: higher patient comfort, (i.e. reduced interference with sleep quality induced by the monitoring system), lower risk of signal loss, and reduced possibility of apneas under-detection in case of prevalent mouth respiration. Moreover, the absence of a nasal cannula is more consistent with the use of the system for a prolonged time, as it could happen for a continuous nighttime and daytime recording [26,27].
We must recognize, however, that the agreement between the two devices drops if respiratory event classification is taken into account. A good accuracy is still present for central and obstructive apneas, but both sensitivity and positive predictive values fall below 50% for hypopneas. This is not surprising if the operating differences between the two recording systems is considered, as the absence of direct respiratory flow measurement becomes, in this case, a major limitation. Indeed, on the basis of the only respiratory movement analysis, discrimination between an obstructive apnea and a hypopnea substantially depends on the presence of thoraco-abdominal asynchrony, because events with a counter-phase angle close to the cut off value could be easily misdiagnosed.
A few study limitations should be acknowledged. Firstly, patients comfort scale while wearing X10X-Y and SOMNOtouch™ RESP were not assessed in the present study. This is due to the simultaneous application of the two systems so that comfort analysis for each device was not possible. Secondly, daily respiratory recordings were not assessed because SOMNOtouch™ RESP is not designed for daily ambulatory monitoring. However in a recent study we analyzed X10X-Y devices continuously for 24 hours in 10 healthy subjects and 30 cardio respiratory patients and observed promising findings [23]. Thirdly, our patients population was unbalanced toward male subjects as expected for a study analazing consecutive patients with sleep disorders. Therefore future studies dedicated to separately assess the capability of X10X and X10Y devices in females and males are needed. Finally, while the quantitative analysis was performed over the entire data recording, the qualitative analysis was performed by visual inspection of 8 minutes samples taken every 30 minutes, choosing intervals in a blind fashion and using a predetermined fixed interval.
In conclusion, the X10X and X10Y devices are a reliable, non-invasive device for recording sleep respiratory behavior, able to provide a correct grading of sleep respiratory disorders when compared to a widely used system for nocturnal cardiorespiratory monitoring like SOMNOtouch™ RESP, even in the absence of direct measurement of the respiratory flow. At present, the X10X and X10Y devices can be considered as a type 3 sleep test device but it should be principally regarded as a screening test for the detection and quantification of sleep respiratory disorders, as well as a daily monitoring system for early detection, to reveal information that would have otherwise been overlooked. On the other hand, the unrequired need of a nasal cannula for respiratory flow measurement presents an excellent step forward for respiratory analysis during the daytime, and for everyday activities.
Supporting information
S1 Fig. Example of grade 1 = poor signal and difficult interpretation.
https://doi.org/10.1371/journal.pone.0249470.s001
(DOCX)
S2 Fig. Example of grade 2 = insufficient signal and questionable interpretation.
https://doi.org/10.1371/journal.pone.0249470.s002
(DOCX)
S3 Fig. Example of grade 3 = sufficient signal and reliable interpretation.
https://doi.org/10.1371/journal.pone.0249470.s003
(DOCX)
S4 Fig. Example of grade 4 = good signal and reliable interpretation.
https://doi.org/10.1371/journal.pone.0249470.s004
(DOCX)
S5 Fig. Example of grade 5 = excellent signal and reliable interpretation.
https://doi.org/10.1371/journal.pone.0249470.s005
(DOCX)
References
- 1. Parati G., et al., Heart failure and sleep disorders. Nat Rev Cardiol, 2016. 13(7): p. 389–403. pmid:27173772
- 2. Redeker N.S., et al., Nocturia, sleep and daytime function in stable heart failure. J Card Fail, 2012. 18(7): p. 569–75. pmid:22748491
- 3. Mills P.J., et al., Sleep and health-related quality of life in heart failure. Congest Heart Fail, 2009. 15(5): p. 228–33. pmid:19751424
- 4. Tkacova R., Wang H., and Bradley T.D., Night-to-night alterations in sleep apnea type in patients with heart failure. J Sleep Res, 2006. 15(3): p. 321–8. pmid:16911035
- 5. Punjabi N.M., et al., Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med, 2009. 6(8): p. e1000132. pmid:19688045
- 6. Eckert D.J., et al., Central sleep apnea: Pathophysiology and treatment. Chest, 2007. 131(2): p. 595–607. pmid:17296668
- 7. Levy P., et al., Sleep apnoea and the heart. Eur Respir Rev, 2013. 22(129): p. 333–52. pmid:23997061
- 8. Gami A.S., et al., Association of atrial fibrillation and obstructive sleep apnea. Circulation, 2004. 110(4): p. 364–7. pmid:15249509
- 9. Somers V.K., et al., Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation, 2008. 118(10): p. 1080–111. pmid:18725495
- 10. Durgan D.J. and Bryan R.M. Jr., Cerebrovascular consequences of obstructive sleep apnea. J Am Heart Assoc, 2012. 1(4): p. e000091. pmid:23130152
- 11. Javaheri S. and Javaheri A., Sleep apnea, heart failure, and pulmonary hypertension. Curr Heart Fail Rep, 2013. 10(4): p. 315–20. pmid:24097114
- 12. Geovanini G.R. and Lorenzi-Filho G., Cardiac rhythm disorders in obstructive sleep apnea. J Thorac Dis, 2018. 10(Suppl 34): p. S4221–S4230. pmid:30687538
- 13. Omran H., et al., Characteristics and circadian distribution of cardiac arrhythmias in patients with heart failure and sleep-disordered breathing. Clin Res Cardiol, 2018. 107(10): p. 965–974. pmid:29740701
- 14. Bradley T.D. and Floras J.S., Sleep apnea and heart failure: Part II: central sleep apnea. Circulation, 2003. 107(13): p. 1822–6. pmid:12682029
- 15. Bradley T.D. and Floras J.S., Sleep apnea and heart failure: Part I: obstructive sleep apnea. Circulation, 2003. 107(12): p. 1671–8. pmid:12668504
- 16. Kapur V.K., et al., Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med, 2017. 13(3): p. 479–504. pmid:28162150
- 17. Yin M., Miyazaki S., and Ishikawa K., Evaluation of type 3 portable monitoring in unattended home setting for suspected sleep apnea: factors that may affect its accuracy. Otolaryngol Head Neck Surg, 2006. 134(2): p. 204–9. pmid:16455365
- 18. Rofail L.M., et al., Comparison between a single-channel nasal airflow device and oximetry for the diagnosis of obstructive sleep apnea. Sleep, 2010. 33(8): p. 1106–14. pmid:20815194
- 19. Rofail L.M., et al., The utility of single-channel nasal airflow pressure transducer in the diagnosis of OSA at home. Sleep, 2010. 33(8): p. 1097–105. pmid:20815193
- 20. Nakano H., et al., Validation of a single-channel airflow monitor for screening of sleep-disordered breathing. Eur Respir J, 2008. 32(4): p. 1060–7. pmid:18480104
- 21. Vogiatzis I., The wireless revolution and cardiorespiratory system monitoring. Int J Cardiol, 2019. 284: p. 81. pmid:30224259
- 22. Walsh J.A. 3rd, Topol E.J., and Steinhubl S.R., Novel wireless devices for cardiac monitoring. Circulation, 2014. 130(7): p. 573–81. pmid:25114186
- 23. Sarmento A., et al., Qualitative and quantitative evaluation of a new wearable device for ECG and respiratory Holter monitoring. Int J Cardiol, 2018. 272: p. 231–237. pmid:30153992
- 24. Berry R.B., et al., AASM Scoring Manual Updates for 2017 (Version 2.4). J Clin Sleep Med, 2017. 13(5): p. 665–666. pmid:28416048
- 25. Giavarina D., Understanding Bland Altman analysis. Biochem Med (Zagreb), 2015. 25(2): p. 141–51. pmid:26110027
- 26. Collop N.A., et al., Obstructive sleep apnea devices for out-of-center (OOC) testing: technology evaluation. J Clin Sleep Med, 2011. 7(5): p. 531–48. pmid:22003351
- 27. Polese J.F., et al., Is portable monitoring for diagnosing obstructive sleep apnea syndrome suitable in elderly population? Sleep Breath, 2013. 17(2): p. 679–86. pmid:22752758